Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/7/2025

Hepatitis C Treatment Considerations

Introduction to Antibiotic Use in Hepatitis C Patients

  • No specific drug-drug interactions have been reported between Bactrim (cotrimoxazole) and direct-acting antiviral (DAA) medications used for hepatitis C treatment 1
  • The American Academy of Dermatology suggests that cotrimoxazole can be safely used in patients with chronic hepatitis B or C, especially in those with cirrhosis, as it appears to be safe and may be associated with reduced risk of spontaneous bacterial peritonitis 2
  • The 2025 North American Clinical Practice Guidelines explicitly support the use of cotrimoxazole in this population 2

Antibiotic Options

  • Cotrimoxazole is suggested as a safe option for patients with chronic hepatitis B or C requiring systemic antibiotics, particularly strong for patients with evidence of cirrhosis, where cotrimoxazole may provide additional benefits beyond its antimicrobial effects 2
  • Ciprofloxacin is suggested as an alternative to cotrimoxazole, particularly in cirrhotic patients 2
  • Doxycycline can be used with an approach similar to non-hepatitis patients 2
  • Exercise caution with rifampin due to its potential hepatotoxicity in hepatitis patients 2

Monitoring and Precautions

  • Cotrimoxazole may interact with other medications metabolized by the liver, with particular caution with methotrexate as cotrimoxazole increases methotrexate levels, and potential interactions with warfarin, phenytoin, and oral hypoglycemic agents 3
  • Standard monitoring should be implemented, including baseline liver function tests before starting treatment, follow-up liver function tests after 2-4 weeks of therapy, and regular monitoring during prolonged treatment courses 2